NASDAQ:SAGE
Sage Therapeutics Stock News
$11.90
-0.440 (-3.57%)
At Close: May 10, 2024
Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
06:30am, Tuesday, 25'th Oct 2022
CAMBRIDGE, Mass.
Can Biogen (BIIB) Navigate Multiple Challenges & Grow Again?
01:15pm, Monday, 03'rd Oct 2022 Zacks Investment Research
Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can
Should WisdomTree U.S. SmallCap ETF (EES) Be on Your Investing Radar?
10:20am, Monday, 05'th Sep 2022 Zacks Investment Research
Style Box ETF report for EES
Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
06:30am, Friday, 02'nd Sep 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will
Is WisdomTree U.S. SmallCap ETF (EES) a Strong ETF Right Now?
10:20am, Tuesday, 30'th Aug 2022 Zacks Investment Research
Smart Beta ETF report for EES
Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help
10:50am, Thursday, 11'th Aug 2022
The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.
Sage Therapeutics, Inc. (SAGE) CEO Barry Greene on Q2 2022 Results - Earnings Call Transcript
12:25pm, Tuesday, 02'nd Aug 2022
Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q2 2022 Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants Helen Rubinstein - IR Barry Greene - CEO Albert Robichaud - Chief Scientific Offi
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates
11:45am, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.39% and 14.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates
09:05am, Tuesday, 02'nd Aug 2022
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.39% and 14.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics to Present at Upcoming August Investor Conferences
06:30am, Monday, 01'st Aug 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will
Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
06:30am, Tuesday, 19'th Jul 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that
Why Shares of Sage Therapeutics Climbed 15.6% This Week
10:20pm, Friday, 03'rd Jun 2022 The Motley Fool
Investors can see the finish line for the company's second marketed therapy.
Why Shares of Sage Therapeutics Climbed 15.6% This Week
06:20pm, Friday, 03'rd Jun 2022
Investors can see the finish line for the company's second marketed therapy.
Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals
07:20pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a phase III study, which evaluated zuranolone to treat postpartum depression in women.
Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals
04:33pm, Thursday, 02'nd Jun 2022
Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a phase III study, which evaluated zuranolone to treat postpartum depression in women.
